Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J3393 Injection, betibeglogene autotemce

J Codes (Drugs)

Also known as: betibeglogene autotemcel, Zolgensma, gene therapy

Betibeglogene autotemcel (Zolgensma) injection is a gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.

In Plain Language

immune system gene therapy; severe immunodeficiency treatment

Clinical Context

Autologous T cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Engineered cells modified with adenosine deaminase gene administered intravenously.

RVU Information

CPT J3393 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

ImmunologyHematologyGene Therapy

Frequently Asked Questions

What is CPT code J3393?

CPT J3393 (Injection, betibeglogene autotemce) is a J Codes (Drugs) code. Betibeglogene autotemcel (Zolgensma) injection is a gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.

How is J3393 administered?

CPT J3393 is administered by a healthcare provider, typically via injection or infusion. Autologous T cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Engineered cells modified with adenosine deaminase gene administered intravenously. It is used by Immunology, Hematology, Gene Therapy.

When is CPT J3393 used?

Autologous T cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Engineered cells modified with adenosine deaminase gene administered intravenously.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.